Quantum Cyber N.V. (QUCY) Stock Price & Analysis
Quantum Cyber N.V. (QUCY) rose 4.61% to USD 1.59 as of September 8, 2026 at 09:37 UTC, according to Nexqual real-time market data.
QUCY last closed at USD 1.59; the session ranged USD 1.51–1.63 on volume of 1,181,483 shares. Market capitalization is —, with a 52-week range of USD 0.3–4.93 (NCM). Source: Nexqual, September 8, 2026 at 09:37 UTC.
Key Statistics (as of September 8, 2026 at 09:37 UTC)
| Price | USD 1.59 |
|---|---|
| Change | ▲ 4.61% (up) |
| Previous Close | USD 1.59 |
| Open | USD 1.59 |
| Day Range | USD 1.51 – 1.63 |
| 52-Week Range | USD 0.3 – 4.93 |
| Volume | 1,181,483 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (QUCY)
Nexqual's technical model rates QUCY "BUY" based on 5 bullish and 1 bearish signals across 128 daily candles, as of September 8, 2026 at 09:37 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 61.61 (neutral) |
| vs SMA50 | Above (USD 1.35) |
| MACD | 0.05 (positive) |
From Quantum Cyber N.V.'s Latest SEC 10-K Filing (filed 2026-03-31)
Key Strengths & Strategy (as disclosed to the SEC)
- In March 2025, we acquired a license from Liquid Bioscience, Inc. to access a portfolio of novel mRNA biomarkers and AI developed proprietary algorithm, for the non-invasive detection of pancreatic cancer with a blood test.
- Our approach integrates proprietary, validated biomarkers with reliable diagnostic tools to optimize accuracy and applicability.
- In the analysis, the biomarkers coupled with the proprietary algorithm developed by Liquid, achieved overall sensitivity of 95% and a 98% specificity for the detection of pancreatic cancer.
-   General   Historically, we have developed and sold in-vitro diagnostic ("IVD") tests for the early detection of cancer.
Partnerships
- Through our agreement with the Université de Sherbrooke, we obtained an exclusive, unilateral option to acquire a license for the UdeS Biomarkers.
- Enabling earlier detection of these diseases allows for earlier and better therapy for affected individuals.   1     Pancreatic Cancer Screening Tests   In March 2025, the Company entered into an Agreement with Liquid Biosciences.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| QTEX | QTREX Quantum Ltd. | USD 0.83 | ▲ 2.14% |
| HCWB | HCW Biologics Inc. | USD 2.94 | ▼ 12.37% |
| AIIO | Robo.ai Inc. | USD 1.84 | ▲ 8.24% |
| SPRC | SciSparc Ltd. | USD 5.29 | ▼ 9.57% |
| ENSC | Ensysce Biosciences, Inc. | USD 0.46 | ▲ 2.93% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 09:37 UTC. This page is informational and not investment advice.